
Study presented at CROI 2024 reveals chronic hepatitis B virus (HBV) infection heightens COVID-19 severity as vaccination reduces mortality and ICU demands in co-infected individuals.

Study presented at CROI 2024 reveals chronic hepatitis B virus (HBV) infection heightens COVID-19 severity as vaccination reduces mortality and ICU demands in co-infected individuals.

Study presented at CROI 2024 reveals that the introduction of Doxycycline post-exposure prophylaxis (doxy-PEP) guidelines in San Francisco has significantly decreased the incidence of chlamydia and syphilis

A new study offers some clues into the pathophysiology and biomarkers of post-acute Sequelae of SARS-CoV-2 (PASC).

From the ongoing CROI meeting, the FDA approved antiretroviral was studied over a 2-year period and showed treatment benefit.

Although the current reimbursement model makes it difficult for pharmaceutical companies to recoup their investments, a subscription model like the prospective congressional bill, the Pasteur Act, may help change that paradigm. In addition, there are international measures being carried out that may bring about changes.

A clinician discusses the ongoing challenges presented with critically ill patients and the timing and scope of antibiotic prescribing practices.

A study showed the Clostridioides difficile treatment remained effective after subsequent systemic antibiotic exposure.

A study presented at IDWeek details some of the shortfalls in utilization.

Contagion attended IDWeek, and here are some of the top stories we reported on while we were there. Continue to catch our coverage in the days to follow!

A number of factors has led to the increased incidence rates, but questions remain if the vector-borne disease's numbers are being captured accurately.

A Centers for Disease Control and Prevention (CDC) epidemiologist provides insights on a large study.

Natural infection plus COVID-19 vaccination in pregnant mothers conferred more durable antibody responses in infants than natural infection alone.

Heather Yun, MD, FACP, FIDS who is this year’s IDWeek Chair for the Infectious Diseases Society of America (IDSA) talks about the honor of the position, the collective effort to put together the conference, and offers insights on AMR during war, as well as new emerging infectious disease threats.

The findings may support further COVID-19 vaccination in children and reduce vaccine hesitancy.

A late-breaking abstract presented at IDWeek reports on the data around the Prefusion F Protein vaccine.

The findings emphasize the importance of reviewing all hepatitis B serology reports prior to switching HIV treatment.

Codagenix is reporting data at this year’s IDWeek for its live-attenuated vaccine candidate, CoviLiv.

The algorithm sought to address high rates of false-positive cultures, excessive antibiotic use, and unnecessary diagnostic procedures in an emergency department setting.

The combination antibiotic was equally effective against both monomicrobial and polymicrobial Acinetobacter baumannii-calcoaceticus Complex infections.

The investigational treatment is being developed for this patient population.

Social determinants such as housing and transportation were strong predictors of patients receiving fecal microbiota transplants (FMT).

The monoclonal antibody demonstrated a significant impact on RSV-related hospitalizations regardless of infant characteristics.

Adding the oral therapy to standard of care helped reduce total days on oxygen for those hospitalized with COVID-19.

Earlier this year, cases of fungal meningitis were discovered at 2 surgical clinics in Matamoros, Mexico. The CDC offers an update on this deadly outbreak.

A study being presented at IDWeek 2023 demonstrated a 2-fold increase in HIV infections associated with barriers to treatment.

Toronto, Canada-based Bluedot offers surveillance tracking information to identify trends for viruses and syndromes efficiently to aid public health officials and other key stakeholders to assess situations and make decisions around this data.

The subject is one where it does not garner the attention of other serious health topics, but key stakeholders say it should.

Earlier this year, the company announced its first foray into these types of infections in developing vaccines for the tickborne infection utilizing its mRNA vaccine platform.

Sam Aitken, PharmD, president-elect of the Society of Infectious Disease Pharmacists (SIDP), discusses how this strategy is one significant part of a complex puzzle to decrease antimicrobial resistance.

Misinformation created unnecessary hospitalizations and mortality and demonstrated the chasm in public health communication.